1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 24,140 | 24,720 | 21.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences | 13 | Benzinga.com | ||
| CARIS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.07. | Cathie Wood's ARK sells Roku, buys Caris Life Sciences stock | 18 | Investing.com | ||
| 14.07. | Wolfe Research startet Coverage für Caris Life Sciences mit "Outperform"-Rating | 3 | Investing.com Deutsch | ||
| 14.07. | Wolfe Research initiates Caris Life Sciences stock with Outperform rating | 3 | Investing.com | ||
| 14.07. | Evercore ISI initiates Caris Life Sciences stock with Outperform rating | 3 | Investing.com | ||
| 14.07. | Citi initiates Caris Life Sciences stock with Buy rating on profitability outlook | 2 | Investing.com | ||
| 14.07. | Caris Life Sciences stock initiated with Buy rating at TD Cowen | 1 | Investing.com | ||
| 14.07. | JPMorgan startet Coverage für Caris Life Sciences mit "Overweight"-Rating | 4 | Investing.com Deutsch | ||
| 14.07. | JPMorgan initiates Caris Life Sciences stock with Overweight rating | 2 | Investing.com | ||
| 14.07. | Guggenheim initiates coverage on Caris Life Sciences stock with Buy rating | 4 | Investing.com | ||
| 14.07. | Guggenheim stuft Caris Life Sciences mit "Buy" ein und sieht 20 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 14.07. | Caris Life Sciences: BTIG startet Coverage mit "Buy" dank führender Rolle in der Präzisionsonkologie | 1 | Investing.com Deutsch | ||
| 14.07. | Caris Life Sciences stock initiated with Buy rating at BTIG on precision oncology leadership | 1 | Investing.com | ||
| 13.07. | BofA Securities initiates coverage on Caris Life Sciences stock with Buy rating | 4 | Investing.com | ||
| 08.07. | Caris Life Sciences validates AI blood test for cancer detection | 1 | Investing.com | ||
| 24.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 24.06.2025 | 660 | Xetra Newsboard | The following instruments on XETRA do have their first trading 24.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.06.2025
Aktien
1 NL0015002J37 JBS N.V.
2 AU0000400616... ► Artikel lesen | |
| 23.06. | Should You Buy Caris Life Sciences Stock After the CAI IPO? | 8 | Barchart.com | ||
| 22.06. | Precision Medicine Firm Caris Breaks Bio IPO Drought, Raising $494M for Cancer Analysis Tools | 8 | MedCity News | ||
| 20.06. | Caris Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.06. | Stonebridge Capital Gains from Caris Nasdaq Listing | 2 | BusinessKorea |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 55,50 | -0,89 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| INTELLIA THERAPEUTICS | 10,890 | +4,91 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 49,600 | -5,52 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer | ||
| IOVANCE BIOTHERAPEUTICS | 2,160 | +12,30 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| 10X GENOMICS | 10,020 | -4,11 % | 10x Genomics, Inc.: 10x Genomics Reports First Quarter 2025 Financial Results | PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| AC IMMUNE | 1,758 | -1,79 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
| MESOBLAST | 1,260 | -1,56 % | Mesoblast Limited: Successful Commercial Launch of Ryoncil | NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales... ► Artikel lesen | |
| COMPUGEN | 1,390 | +5,14 % | Compugen Ltd.: Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer | Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer
Trial supported... ► Artikel lesen | |
| KRYSTAL BIOTECH | 126,05 | -0,75 % | Hedge Fund and Insider Trading News: Bobby Jain, Bill Ackman, Ken Griffin, Sylebra Capital Management, Millennium Management, Krystal Biotech Inc (KRYS), and More | ||
| NEWAMSTERDAM PHARMA | 19,200 | +1,05 % | Goldman Sachs nimmt Beobachtung von NewAmsterdam Pharma mit "Neutral" auf | ||
| ACUMEN PHARMACEUTICALS | 1,540 | +1,99 % | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease | Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical... ► Artikel lesen | |
| EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? |
Das Unternehmen CARIS LIFE SCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,62 % bei einem Aktienkurs von 24,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARIS LIFE SCIENCES INC finden Sie auf Wallstreet Online.